545 related articles for article (PubMed ID: 26059964)
1. Safety of anticoagulant treatment in cancer patients.
Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
[TBL] [Abstract][Full Text] [Related]
2. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
[TBL] [Abstract][Full Text] [Related]
3. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
[TBL] [Abstract][Full Text] [Related]
7. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
8. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
Pritchard ER; Murillo JR; Putney D; Hobaugh EC
J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
10. Prevention of deep vein thrombosis in cancer patients.
Lee AY
Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant use in cancer patients.
Trujillo-Santos J; Monreal M
Expert Opin Pharmacother; 2011 Feb; 12(3):351-62. PubMed ID: 21254944
[TBL] [Abstract][Full Text] [Related]
12. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence.
Hull RD; Townshend G
Thromb Haemost; 2013 Jul; 110(1):14-22. PubMed ID: 23615656
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
17. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
Patel A; Williams H; Baer MR; Zimrin AB; Law JY
Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
19. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]